相关实验视频

Updated: Jul 26, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

低分离放射疗法与免疫化学疗法用于扩展阶段的小细胞肺癌

Chaoyuan Liu¹, Liang Zeng², Chao Deng¹

¹Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Frontiers in immunology

|June 23, 2023

概括

在扩大阶段小细胞肺癌 (ES-SCLC) 的第一线免疫化学疗法中添加并发的低分离胸部放射治疗,表明耐受性良好,有效性有前途. 需要进一步的随机试验来确认这些好处.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
辐射疗法辐射疗法

背景情况:

扩散阶段小细胞肺癌 (ES-SCLC) 的标准第一线治疗包括与碳白/白和埃托 (EC/EP) 结合的PD-L1抑制剂.
与免疫化学疗法同时进行息性低分离胸部放射治疗 (HFRT) 可能在ES-SCLC治疗中提供协同效益.

研究的目的:

探索一种最佳的模型,将放射治疗与免疫化学疗法作为ES-SCLC的第一线治疗.
评估这种综合方法的安全性,耐受性和有效性.

主要方法:

一个多中心,单臂的第二阶段试验,涉及40名ES-SCLC患者.
患者接受了阿特佐利祖马布与EC/EP两轮治疗,随后进行并发性息性HFRT,并且在没有进展的患者中接受了阿特佐利祖马布与EC/EP两轮治疗.
维护期阿特佐利祖马布每3周给予一次,长达2年;推预防性部照射 (PCI).

主要成果:

所有40名患者都完成了HFRT和四次免疫化学疗法.
报告了7次3级不良事件和2次4级不良事件;没有发生5级毒性.
无进展生存时间 (PFS) 中位数为8.6个月 (95% CI,6.1-11.1),随访时间中位数为14.2个月.

结论:

与ES-SCLC的第一线免疫化学疗法同时进行HFRT是耐受良好的.
这种组合疗法显示出有前途的临床疗效,需要进一步研究.
需要额外的随机试验来验证这种治疗策略的好处.

关键词:

扩散阶段的小细胞肺癌.免疫化学疗法免疫化学疗法没有进展的生存率.在安全方面,安全是安全的.胸部辐射胸部辐射

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...